"id","instanceType","rationale","uuid:ID","versionIdentifier"
"StudyVersion_1","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","f02d65af-ee67-49c6-b2cc-ee22e04c584d","2"
